Percutaneous Alginate Hydrogel Endomyocardial Injection with a Novel Dedicated Catheter Delivery System: An Animal Feasibility Study.
Bo WangChao GaoScott LimRutao WangCun-Jun ZhuYoshinobu OnumaYunbing WangRunlin GaoPatrick W J C SerruysRandall J LeeLing TaoPublished in: Journal of cardiovascular translational research (2024)
The objective of this preclinical study was to evaluate the feasibility and safety of transcatheter endocardial alginate hydrogel injection (TEAi) in a large animal model, utilizing the high-stiffness XDROP® alginate hydrogel in combination with the dedicated EndoWings® catheter-based system. All swine (n = 9) successfully underwent TEAi without complications. Acute results from a subset of animals (n = 5) demonstrated the ability of the catheter to access a wide range of endomyocardial areas and achieve consecutive circumferential hydrogel distribution patterns within the mid-left ventricular wall. Histological examinations at 6 months (n = 4) demonstrated that the XDROP® remained localized within the cardiac tissue. In addition, serial echocardiographic imaging showed that XDROP® had no adverse impacts on LV systolic and diastolic functions. In conclusion, this innovative combination technology has the potential to overcome the translational barriers related to alginate hydrogel delivery to the myocardium.
Keyphrases
- left ventricular
- wound healing
- tissue engineering
- ultrasound guided
- drug delivery
- hyaluronic acid
- cardiac resynchronization therapy
- heart failure
- hypertrophic cardiomyopathy
- mitral valve
- blood pressure
- acute myocardial infarction
- left atrial
- high resolution
- aortic stenosis
- liver failure
- risk assessment
- cell therapy
- minimally invasive
- risk factors
- intensive care unit
- bone marrow
- hepatitis b virus
- ejection fraction
- coronary artery disease
- photodynamic therapy
- electronic health record
- respiratory failure